EP2 Receptor Agonists for Glaucoma Intraocular Pressure Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary and secondary glaucoma, face challenges in effectively managing intraocular pressure due to obstruction of aqueous humor outflow, with existing ocular hypotensive agents having limitations in efficacy and specificity.
Innovation Solution
Development of compounds acting as selective EP2 agonists, specifically designed to target and manage glaucoma by modulating intraocular pressure through selective agonism of prostaglandin EP2 receptors, which are administered as pharmaceutically acceptable salts or prodrugs to enhance ocular hypotensive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure can be reduced, but the treatment lacks specificity and efficacy is limited
Solution Approach 1:
The patent changes the pharmacological parameter from β-adrenoreceptor antagonism to prostaglandin EP2 receptor agonism. This fundamental parameter change enables both improved efficacy in reducing intraocular pressure and enhanced specificity through selective receptor targeting, thereby resolving the technical contradiction between reliability and adaptability.
Solution Approach 2:
The patent introduces prostaglandin EP2 selective agonists as a new intermediary substance to mediate the therapeutic effect. This intermediary selectively binds to EP2 receptors in the ocular tissue, providing targeted action that improves both efficacy and specificity compared to non-selective β-adrenoreceptor antagonists.
2Reliability
If existing ocular hypotensive agents are used, then some pressure reduction effect is achieved, but the treatment effectiveness is insufficient for managing intraocular pressure
Solution Approach 1:
The patent applies parameter changes by transitioning from existing ocular hypotensive agents to prostaglandin EP2 selective agonists with optimized pharmacological parameters. This includes selective receptor binding affinity and improved pharmacokinetic properties, resulting in enhanced treatment effectiveness and efficacy for managing intraocular pressure.
Data Source
AI summary
Compounds comprising:or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y is a carboxylic acid functional group, sulfonic acid functional group, or phosphonic acid functional group; or an amide or ester thereof comprising from 0 to 12 carbon atoms; or Y is a hydroxymethyl, or tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH═CH—(CH2)3—, or —CH2C≡C—(CH2)3—, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is —(CH2)m—Ar—(CH2)o wherein Ar is substituted or unsubstituted phenyl or monocyclic heteroaryl, the sum of m and o is from 1 to 4, and wherein one CH2 may be replaced by with S or O; R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed.